More than 86,000 recorded cases of respiratory syncytial virus in 2024 were in children younger than four years old.

COVID-19 was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...

While RSV isn’t any more virulent than the cold, flu or COVID, the same precautions are recommended in order to control its ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

As new viruses like COVID-19, bird flu, norovirus, and RSV (respiratory syncytial virus) continue to spread, vaccines have ...

Among adults aged 75 and older, RSV was linked to a substantial burden of hospitalizations, ICU admissions, and in-hospital deaths before vaccines were available.

The topic and treatment of contagious disease has become controversial since COVID-19 came along, but what is not ...

COVID-19 continues to be a threat to America's health, causing more illness and death than either influenza or respiratory ...

WEDNESDAY, Jan. 29, 2025 (HealthDay News) -- COVID-19 continues to be a threat to America’s health, causing more illness and ...

People with diabetes and obesity are at higher risk for severe respiratory illness caused by viruses, including serious ...

ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense immune enhancers to minimize the impact of respiratory viral infections in at-risk populations, announces ...